Leede Financial Has Negative Outlook of THTX FY2026 Earnings

Theratechnologies Inc. (NASDAQ:THTX) – Equities research analysts at Leede Financial cut their FY2026 EPS estimates for Theratechnologies in a note issued to investors on Monday, April 14th. Leede Financial analyst D. Loe now anticipates that the company will post earnings per share of $0.12 for the year, down from their previous estimate of $0.15. The consensus estimate for Theratechnologies’ current full-year earnings is $0.01 per share. Leede Financial also issued estimates for Theratechnologies’ FY2027 earnings at $0.20 EPS.

Other research analysts have also issued reports about the company. Research Capitl raised Theratechnologies to a “strong-buy” rating in a research report on Friday, February 14th. Jones Trading raised Theratechnologies from a “hold” rating to a “strong-buy” rating in a research note on Friday, April 11th.

Theratechnologies Stock Down 3.4 %

Shares of NASDAQ:THTX opened at $2.57 on Tuesday. The firm has a fifty day moving average of $1.67 and a two-hundred day moving average of $1.54. Theratechnologies has a 12-month low of $1.08 and a 12-month high of $3.13. The firm has a market capitalization of $118.17 million, a P/E ratio of -25.70 and a beta of 1.11.

Institutional Investors Weigh In On Theratechnologies

Several institutional investors and hedge funds have recently modified their holdings of the business. National Bank of Canada FI lifted its stake in shares of Theratechnologies by 29.4% in the third quarter. National Bank of Canada FI now owns 186,815 shares of the company’s stock worth $232,000 after buying an additional 42,435 shares during the last quarter. Harbour Investments Inc. raised its holdings in Theratechnologies by 20.0% in the 4th quarter. Harbour Investments Inc. now owns 87,772 shares of the company’s stock worth $159,000 after acquiring an additional 14,655 shares during the period. Wealthspire Advisors LLC lifted its position in Theratechnologies by 39.0% during the 4th quarter. Wealthspire Advisors LLC now owns 71,250 shares of the company’s stock worth $129,000 after acquiring an additional 20,000 shares during the last quarter. Hillsdale Investment Management Inc. bought a new stake in Theratechnologies during the fourth quarter valued at about $108,000. Finally, Virtu Financial LLC bought a new position in shares of Theratechnologies in the fourth quarter worth about $40,000.

Theratechnologies Company Profile

Theratechnologies Inc, a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen.